Key takeaways
Victoza (liraglutide) and Wegovy (semaglutide) are both GLP-1 receptor agonists, and they share some similarities in their ability to lower the risk of heart-related problems in adults with heart disease. However, they have different primary uses and dosing schedules. Victoza is FDA-approved to treat Type 2 diabetes in people aged 10 and older and is injected once daily. It can also help with weight loss, but this is considered an off-label use and is a side effect of th medication. On the other hand, Wegovy is FDA-approved for long-term weight management in adults and children aged 12 and older with certain BMI criteria and is injected once a week. While both medications can cause side effects like nausea and diarrhea, Wegovy tends to cause these side effects more often. Additionally, both medications carry a risk of thyroid cancer and pancreatitis, but Wegovy also has warnings about potential eye problems and faster heart rates. Victoza is available as a lower-cost generic, while Wegovy is only available as a branded medication.
